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Introduction
If I ask my daughter to give me three key dates in the history of Rome, I expect
her to say: 753 BC (the foundation of the city), 44 BC (the murder of Julius Cesar)
and 476 AD (the fall of the Roman Empire). If I am asked to provide three key dates
for polycythemia vera (PV), I will say: 1892, the date of the first description by
Louis Henri Vaquez which was then  reinforced by William Osler's report in 1903,1
1951, when William Dameshek grouped together PV, myelofibrosis (MF) and
essential thrombocythemia (ET) under the term “myeloproliferative disorders”,2
and 2005, when William Vainchenker,3 Tony Green,4 Ross Levine5 and Robert
Kralovics6 independently described the JAK2V617F mutation. It is fascinating that
the original speculation by Vaquez that PV was due to hematopoietic hyperactivi-
ty, and the illuminating hypothesis of Dameshek that all myeloproliferative disor-
ders [now known as myeloproliferative neoplasms (MPN)]7 variably reflected
increased proliferative activity of bone marrow (BM) cells “due to a hitherto undis-
covered stimulus”,2 were both reconciled by the demonstration of abnormal acti-
vation of JAK/STAT signaling as the unifying pathogenetic mechanism. However,
beyond these groundbreaking discoveries, the history of PV is punctuated by
achievements that have  contributed to various degrees to improve our understand-
Polycythemia vera is a clonal disorder of hematopoietic stem/progen-itor cells. It manifests as an expansion of red cell mass. It is the mostcommon chronic myeloproliferative neoplasm. In virtually all cases,
it is characterized by a V617F point mutation in JAK2 exon 14 or less
common mutations in exon 12. The landmark discovery of the
autonomously activated  JAK/STAT signaling pathway paved the way for
the clinical development of the first target drug, the JAK1 and JAK2
inhibitor ruxolitinib. This is now approved for patients with resistance or
intolerance to hydroxyurea. Phlebotomies and hydroxyurea are still the
cornerstone of treatment, and aim to prevent the first appearance or
recurrence of cardiovascular events that, together with progression to
post-polycythemia vera myelofibrosis and leukemia, represent the main
causes of death. Interferon-a is an alternative drug and has been shown
to induce molecular remissions. It is currently  undergoing phase III trials
that might eventually lead to its approval for clinical use. The last few
years have witnessed important advances towards an accurate early diag-
nosis of polycythemia vera, greater understanding of  its pathogenesis,
and  improved patient management. This review will focus on the most
recent achievements and will aim to unify the different concepts involved
in a personalized approach to the patient with polycythemia vera. In
spite of many recent advances in the understanding of its pathogenesis
and improved disease management, polycythemia vera remains a life-
threatening myeloproliferative neoplasm for which there is no cure. This
review will present a critical overview of evolving concepts in diagnosis
and treatment of this disease. 
From leeches to personalized medicine:
evolving concepts in the management 
of polycythemia vera
Alessandro M. Vannucchi
CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda
Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica,
Università degli Studi, Firenze, DENOTHE Excellence Center, Italy 
ABSTRACT
ing to the level of knowledge  we have now. Table 1 lists
some of these landmark studies; due to space constraints,
I will not be able to address all of them in detail. 
Evolving concepts in diagnosis 
Making a diagnosis of polycythemia vera
The World Health Organization (WHO) recently released
a revised classification of MPN in which important changes
to the 2008 version were introduced (Table 2).8 In the 2008
version, the most compelling innovation had been the intro-
duction of JAK2V617F and “similar” mutations (involving
JAK2 exon 12 in 3%-4% of patients) as major diagnostic cri-
teria.3-6 Although JAK2V617F mutation is associated with
PV in more than 95% of cases, it does not represent a clear
diagnosis since it is found also in 50%-60% of ET and PMF.
However, the use of JAK2V617F as a marker of clonal
myeloproliferation greatly facilitates the distinction of PV
from reactive or congenital erythrocytosis. 
Considering that isotope-based assays for measuring red
cell mass (RCM) and plasma volume are not routinely avail-
able even in most tertiary centers, the 2008 WHO classifi-
cation listed a hemoglobin level more than 185 g/L and 165
g/L in men and women, respectively, as a strong surrogate
marker of absolute increase of RCM. Since some PV
patients do not fulfill such high levels, other criteria were
added to facilitate diagnosis, including: 1) hemoglobin or
hematocrit level that is more than 99th percentile of refer-
ence range for age, sex, or altitude of residence; 2) an RCM
that is more than 25% above mean normal predicted value;
3) a hemoglobin level more than 170 g/L and 150 g/L in men
and women, associated with a sustained increase of 20 g/L
from baseline not attributable to correction of iron deficien-
cy. According to the pragmatic British standards,  hemat-
ocrit more than 52% in males and more than 48% in
females, or an RCM more than 25% above predicted value,
are sufficient to establish a diagnosis of PV if JAK2mutation
is present.9 However, a reassessment of how far the WHO
criteria can be applied in a real-life setting raised the issue of
JAK2V617F mutated patients with only a borderline
increase in hemoglobin. It was shown that BM morpholo-
gy, according to WHO guidelines, accurately reflected a
condition of increased RCM, since all patients with
increased RCM also had a BM morphology consistent with
PV.10 In 140 such patients, Barbui et al. delineated a category
operationally defined as “masked” PV11 that includes a
majority of early cases, in which thrombocytosis is the ini-
tial disease manifestation, mimicking ET. Additional fea-
tures that distinguish masked from overt PV include male
predominance, higher incidence of arterial thrombosis and
progression to post-PV myelofibrosis (PPV-MF) and acute
leukemia (AL), resulting in inferior survival. Therefore,
masked PV is a heterogeneous condition including early
forms of PV as well as a distinct phenotype with a more
aggressive course. The identification of masked PV might
also reconcile differences in reported incidence of transfor-
mation of JAK2V617F mutated ET to PV.12-14 The best cut off
for hemoglobin/hematocrit to discriminate JAK2V617F
mutated ET from PV was set at 165 g/L/49% in males and
160 g/L/48% in females.15
These findings constituted the backbone for the 2016
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Table 1. Landmark studies in understanding polycythemia vera and its diagnosis and management.
Domain Field of investigation/Study Findings / Comments
Natural history
• Description • First description by L. Vaquez, first review by W. Osler1
• Classification • W. Dameshek theorizes the concept of “myeloproliferative disorders”2
• Natural history • A cohort study on the natural history of PV by the Gruppo Italiano Studio Policitemia111
• Natural history • An international study on natural history of contemporary PV patients23
Pathophysiology
• Clonality • Involvement of a hematopoietic stem/progenitor cell established by analysis of
G6PDH isoenzymes112
• EEC • Cytokine independent growth of erythroid progenitor cells16
• Molecular basis • Description of the JAK2V617F mutation3-6
• Molecular basis • Description of mutations in JAK2 exon 12113
• Molecular basis • Occurrence of non-driver somatic mutations114
Diagnosis
• PVSG criteria • Development of formal diagnostic criteria40
• WHO 2008 • Introduces JAK2mutations as major diagnostic criteria7
• WHO 2016 • Introduces BM biopsy as major diagnostic criterion and adopts the concept of 
“masked” PV8
Management
• Thrombosis and hematocrit • Points to hematocrit >45% as main risk factor for thrombosis77
• PVSG-01 trial • Use of phlebotomy; leukemogenic risk of 32P and chlorambucil39
• PVSG-08 trial • Efficacy of hydroxyurea115
• ECLAP trial • Low-dose aspirin for prevention of CV events55
• CytoPV trial • Evidence-based setting of the optimal hematocrit level at <45%79
• FPSG long-term trial • Leukemogenic risk with pipobroman41
• Interferon study • First sound evidence of an impact of interferon on molecular remission86
• RESPONSE trial • Ruxolitinib for patients with resistance/intollerance to hydroxyurea73
G6PDH: glucose-6-phosphate dehydrogenase, an X-linked locus; EEC: endogenous erythroid colonies; CV: cardiovascular; PVSG: Polycythemia Vera Study Group; Cyto-PV:
Cytoreductive Therapy in PV trial; ECLAP: European Collaboration on Low-dose Aspirin in PV trial; RESPONSE: Randomized Study of Efficacy and Safety in Polycythemia Vera
with JAK Inhibitor INCB018424 versus Best Supportive Care; FPSG: French Polycythemia Study Group.
revision of WHO criteria, where main changes regarded the
threshold level of hemoglobin/hematocrit, the upgrade of
BM biopsy to major criterion, and the abandonment of
endogenous erythroid colony assay16 as minor criterion8
(Table 2). Subnormal erythropoietin levels remain the only
accessory criterion, although in more than 20% of cases the
levels fall within normal range. It has been argued that these
novel criteria might promote an increased usage of BM
biopsy in the diagnostic path of erythrocytosis. However, in
JAK2mutated cases that present hemoglobin levels fulfilling
the 2008 criteria, biopsy is not required for diagnosis,
although it may be recommended, especially in younger
subjects, to assess initial fibrosis that predicts an accelerated
progression to PPV-MF.17 Conversely, biopsy is mandatory
when hemoglobin/hematocrit are at the lower threshold
level set by the 2016 criteria, and early PV must be distin-
guished from JAK2V617F mutated ET. Misdiagnosis with
ET would mean that many patients would only receive sub-
optimal control of hematocrit.18
Diagnosis of transformation to post-polycythemia 
vera myelofibrosis
Post-polycythemia vera myelofibrosis (PPV-MF) represents
a natural evolution of PV. Diagnostic criteria have been out-
lined by the International Working Group-
Myeloproliferative neoplasms Research and Treatment
(IWG-MRT) expert consensus (Table 3).19 The major criterion
is the development of BM fibrosis grade 2 or higher (in the
European scale;20 ≥grade 3 in the conventional scale21) in the
context of a previous diagnosis of PV. It is worthy of note that
the 2016 WHO revision enlists criteria for semiquantitative
grading of BM fibrosis on a scale from 0 to 3. Additional vari-
ables, two of which are required to establish diagnosis, are:
1) anemia or sustained loss of need for phlebotomy and/or
cytoreductive therapy; 2) leukoerythroblastic peripheral
blood; 3) the new appearance, or progression, of
splenomegaly; 4) development of constitutional symptom(s). 
Based on several small historical series (reviewed by
Cerquozzi and Tefferi22) and a recent large study with
mature survival data,23 the median time to myelofibrosis
transformation ranges from 8.5 to 20 years and the cumu-
lating risk increases from 6% to 14% to 26% at 10, 15 and
20 years, after the initial diagnosis, respectively. Older age,
leukocytosis, high JAK2V617F allele burden (that usually
increases further along with transformation),24,25
splenomegaly and thrombocytosis have all been associated
with increased risk of PPV-MF.23-26 More recently, the inde-
pendent value of BM fibrosis at diagnosis of PV17 and the
clinical phenotype of masked PV were recognized. Of 526
PV patients, 14% showed grade 1 fibrosis; this group was
characterized by a higher prevalence of palpable
splenomegaly and greater risk of progression to overt
myelofibrosis [incidence rate (IR) 2.2 per 100 patient-years
vs. 0.8 for those without fibrosis].17 Furthermore, the com-
bined rate of transformation to PPV-MF and AL was signif-
icantly higher among patients with masked PV compared
with overt PV (1.60 vs. 0.97 per 100 patient-years, respec-
tively). Preliminary evidence suggests that chromosome 12
abnormalities are associated with a greater likelihood to
progress to PPV-MF.27
Occurrence of PPV-MF signifies a dramatic shortening of
PV survival to a median of approximately six years with an
adjusted hazard ratio (HR) of 2.17.26 A longer (>10 years)
duration of the chronic PV phase is also associated with
shortened survival after transformation to PPV-MF (HR
2.26).28 According to a dynamic prognostic model, presence
of any of 3 independent variables (anemia, thrombocytope-
nia and leukocytosis) resulted in a 4.2-fold increase in the
risk of death; in particular, occurrence of anemia at PPV-MF
was associated with shortened survival (1.9 vs. 6.6 years for
non-anemic patients).26 However, in clinical practice, and in
clinical trials,29,30 prognostication assessment of PPV-MF
patients is usually performed with the International
Prognostic Scoring System (IPSS) and the dynamic
International Prognostic Scoring System (DIPSS), originally
developed for PMF.31,32 In fact, these scores have not been
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Table 2. The 2016 WHO revised diagnostic criteria for polycythemia vera.8
Major criteria:
1. Hemoglobin > 165 g/L or, 
Hematocrit > 49% in men 
Hemoglobin > 160 g/L or, 
Hematocrit > 48% in women 
or, increased red cell mass*
2. BM biopsy showing hypercellularity for age with trilineage 
growth (panmyelosis) including prominent erythroid, granulocytic and 
megakaryocytic proliferation with pleomorphic, mature megakaryocytes
(differences in size)**
3. Presence of JAK2V617F or JAK2 exon 12 mutation
Minor criterion:
Subnormal serum erythropoietin level
Diagnosis of PV requires meeting either all three major criteria, 
or the  first two major criteria and the minor criterion**
WHO: World Health Organization; BM: bone marrow; PV: polycythemia vera. *More than
25% above mean normal predicted value. **Criterion number 2 (BM biopsy) may not
be required in cases with sustained absolute erythrocytosis: hemoglobin levels more
than 185 g/L in men (hematocrit 55.5%) or more than 165 g/L in women (hematocrit
49.5%) if major criterion 3 and the minor criterion are present. However, initial myelofi-
brosis (present in up to 20% of patients) can only be detected by performing a BM biop-
sy; this finding may predict a more rapid progression to overt myelofibrosis (post-PV
MF).
Table 3. The IWG-MRT recommended diagnostic criteria for  post-poly-
cythemia vera myelofibrosis.19
Required criteria:
1. Documentation of a previous diagnosis of PV as defined by 
the WHO criteria 
2. BM fibrosis grade 2–3 (on 0–3 scale) or grade 3–4 (on 0–4 scale)*
Additional criteria (two are required):
1. Anemia** or sustained loss of requirement for either phlebotomy 
(in the absence of cytoreductive therapy) or cytoreductive treatment 
for erythrocytosis
2. A leukoerythroblastic peripheral blood picture
3. Increasing splenomegaly, defined as either an increase in palpable
splenomegaly of ≥ 5 cm (distance of tip of the spleen from LCM) 
or the appearance of a newly palpable splenomegaly
4. Development of ≥ 1 of 3 constitutional symptoms: > 10% weight loss 
in 6 months, night sweats, and unexplained fever (> 37.5°C)
IWG-MRT: International Working Group for Myeloproliferative neoplasms Research
and Treatment; PV: polycythemia vera; WHO: World Health Organization; BM: bone
marrow; LCM: left costal margin. Diagnosis is made with the 2 required criteria plus 2
additional criteria. *Grade 2–3 according to the European classification20: diffuse,
often coarse fiber network with no evidence of collagenization (negative trichrome
stain) or diffuse, coarse fiber network with areas of collagenization (positive
trichrome stain). Grade 3–4 according to the standard classification21: diffuse and
dense increase in reticulin with extensive intersections, occasionally with only focal
bundles of collagen and/or focal osteosclerosis or diffuse and dense increase in reti-
culin with extensive intersections with coarse bundles of collagen, often associated
with significant osteosclerosis. **Below the reference range for appropriate age, sex,
and altitude considerations.
validated in PPV-MF and they may not perform adequately
in distinguishing different risk categories.28,33 Finally,
although the mutation landscape of PPV-MF has similarities
with PMF,34 in contrast with PMF, little impact of mutations
on prognosis was demonstrated.28 
Diagnosis of transformation to blast phase
A consensus has been achieved as to the definition of
accelerated and blast phase disease in PV (and other MPN)
as being characterized by peripheral or BM blast percent-
ages of 11%-19% and more than 20%, respectively.35 Rate
of transformation to AL is estimated at 2%, 5%, and more
than 10% at 10, 15 and 20 years.23,36 Risk factors for
leukemic transformation include advanced age, leukocyto-
sis, splenomegaly and abnormal karyotype.22,23 There is no
specific molecular marker that is predictive of blast transfor-
mation; interestingly, leukemic blasts may result JAK2wild
type, suggesting the emergence of an unrelated leukemic
clone.37
The promoting role of cytotoxic therapy in the events
leading to blast transformation of PV remains a subject of
major debate.38 The leukemogenic potential of 32P and alky-
lating agents (chlorambucil and pipobroman) was demon-
strated by the PVSG39,40 and the French Polycythemia Study
Group.41 The randomized PVSG-01 study reported an
excess of late-appearing AL in patients treated either with
chlorambucil or 32P (13.2% and 9.6%, respectively) com-
pared with phlebotomy (1.5%).39 The latest update after a
median follow up of 16 years of a French study that ran-
domized PV patients under 65 years of age  to receive pipo-
broman or hydroxyurea as first-line therapy reported signif-
icantly shorter survival in the pipobroman group (15.4 years
vs. 20.3 years for patients treated with hydroxyurea) and
significantly higher cumulative incidence of leukemia (13%,
34% and 52% vs. 6.6%, 16.5%, 24% for hydroxyurea, at
10, 15 and 20 years), although transformation to PPV-MF
was lower in the pipobroman group (21% vs. 32% at 20
years).41 Similar findings were reported in a retrospective
cohort of more than 1500 patients with PV;23 in this study,
the use of hydroxyurea or busulphan alone was not bur-
dened with increased leukemia rate, similar to findings of
the prospective ECLAP cohort.42 However, the use of 2 or
more cytotoxic agents, including hydroxyurea, was associ-
ated with a 2.9 increased odds of leukemia.43 Although it is
not possible to verify whether such an increased rate of
transformation in patients receiving multiple lines of thera-
Management of polycythemia vera
haematologica | 2017; 102(1) 21
Figure 1. The burden of disease in a patient with polycythemia vera. Shown is the famous drawing Uomo Vitruviano of Leonardo da Vinci (1490), named after the
ancient roman architect Vitruvius. Here the ideal man is represented as perfectly inscribed in both a square and a circle. In the figure, this concept is used to signify
the appropriateness of a modern approach to the patient with PV that ideally takes into account the multiplicity of aspects associated with the disease.
py is directly caused by drugs or rather reflects a more
aggressive disease, the decision to shift to second-line ther-
apy in patients previously treated with hydroxyurea must
consider the risk associated with the use of multiple cyto-
toxic agents. In this regard, there is no evidence of a leuke-
mogenic effect of interferon.44 Furthermore, in a nested-case
control study of 162 MPN patients, of which the majority
(68%) were PV, 25% of those who transformed to AL had
never been exposed to cytotoxic therapy, thereby reinforc-
ing the contention that individual genetic characteristics are
themselves causative of the inherent propensity of PV to
transform to AL or myelodysplastic syndrome (MDS).43
Evolving concepts in understanding predisposition
to polycythemia vera
Polycythemia vera, as all MPN, shows a familial aggrega-
tion whereby it has been calculated that first-degree rela-
tives have a 5-7-fold higher risk of developing an MPN in
comparison to the general population.45,46 Clinical presenta-
tion, rate of thrombosis and survival of familial cases are
similar to sporadic MPN.46,47 The JAK2V617F mutation is
acquired somatically in familial cases of PV as in sporadic
patients. The genetic basis of familial aggregation of MPN
have not yet been clarified, although it is likely that patients
inherit some predisposition to acquire one of the driver
mutations.46 In sporadic cases, the JAK2 46/1 haplotype has
been associated with the acquisition of JAK2V617F muta-
tion.48,49 A high incidence of PV among Ashkenazi Jewish
descent has been described,50 but there are  no clues as to
genetic background.
No association between an excess risk of PV and blood
donation or  donation frequency has been observed in a
study involving 1.4 million donors,51 refuting previous
reports in smaller series.52
Evolving concepts in patient management 
Risk stratification
Polycythemia vera is associated with reduced life
expectancy, primarily because of hematologic progression
and cardiovascular events.23,36,53 Analysis of the most mature
survival data clearly shows the shorter life expectancy.
Among 337 patients followed at the Mayo Clinic, of whom
44% died, median survival was 14.1 years; significantly
shorter than the control population.23 Risk factors for overall
survival independent of the cause included advanced age,
leukocytosis, venous thrombosis, and abnormal karyotype.
Median survival was 10.9 and 27.8 years in high- and low-
risk patients, respectively23 (Table 4). However, this score is
not used for decision making in clinical practice.
Approximately 15% of patients with PV may experience
a thrombotic event during the  disease course. Major throm-
botic events are transient ischemic attacks, stroke, myocar-
dial infarction, deep venous thrombosis or pulmonary
embolism, peripheral arterial and venous thrombosis.
Microvascular symptoms, such as hearing or visual impair-
ments, paresthesia, or headache, are common. Venous
thrombosis in unusual sites, particularly the splanchnic
veins (SVT; portal, mesenteric, splenic), Budd-Chiari syn-
drome, thrombosis of the cerebral venous sinuses and cen-
tral retinal vein are more frequent than in the general popu-
lation. History of thrombosis is the main risk factor for
recurrent cardiovascular events that occurred in the same
vessel district as the first event in 75% and 61% of arterial
and venous thrombosis, respectively;54 history of hyperten-
sion predicts for arterial thrombosis and advanced age pre-
dicts for venous thrombosis. The frequency of arterial
(16%) and venous (7.4%) thrombosis in 1818 patients diag-
nosed in the last decade was lower than in previous histor-
ical cohorts, including the ECLAP study (27% and 11%,
respectively),55,56 but was similar to the contemporary Cyto-
PV study (arterial 17%, venous 12%) and the Swedish reg-
istry.57 However, it is remarkable that while a reduction of
thromboses from 4.01 to 2.93 per 100 patient-years was
seen in the “high-risk” category, the rate of vascular events
was unchanged in the “low-risk” category (2.03 vs. 2.24),
thereby suggesting some under-treatment of these conven-
tionally-defined low-risk subjects.58 This is supported by the
unexpected higher rate of thrombosis in young patients
(age < 40 years) with masked PV compared with overt PV
(3.01 vs. 1.99 per 100 patient-years, respectively). In multi-
variate analysis, the only factor accounting for such a differ-
ence was the less frequent use of phlebotomies and cytore-
duction in younger patients with masked PV.18
The current risk stratification, informing therapeutic deci-
sions, is designed to estimate the likelihood of developing
thrombotic complications, and not necessarily the overall
survival (Table 4). Age of 60 years or over and history of
previous thrombosis are used to classify patients into a low-
(neither present) or high- (either present) risk category. An
important element for risk stratifıcation is the comprehen-
sive assessment of additional risk factors for thromboem-
bolism, including smoking,59 hypertension, diabetes, abnor-
mal lipid levels, and obesity. The individual should be made
aware of the value of a healthy life style in minimizing
thrombotic risk, and encouraged to adopt appropriate
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Table 4. Criteria used for risk stratification in polycythemia vera.
Criteria Variables Risk Used for risk-
categories adopted therapy
Thrombotic risk56 • Age > 60 • Low (neither present) Yes
• Previous thrombosis • High (either present)
Shortened survival risk23 • Age • Low (0 points) No
(57-66 years = 2 points) • Intermediate (1-2 points)
(≥ 67 years = 5 points) • High (> 3 points)
• Leukocytes > 15x109/L (= 1 point)
• Venous thrombosis (= 1 point)
Thrombosis • Leukocytosis59 Not yet formally included
• JAK2V617F allele burden60 in risk scores
• Generic cardiovascular risk factors59
measures to correct bad habits. However, generic cardio-
vascular risk factors, as well as leukocytosis59 and higher
JAK2V617F allele burden,60 that have all been associated
with higher risk of thrombosis, are not formally integrated
into current scores. 
Recognizing the burden associated with disease
Although symptoms typically associated with PV have
been well known since initial descriptions, it is only recent-
ly that a full appreciation of their complexity, extent and
impact has been acknowledged.61 Components of the dis-
ease-associated burden include symptomatic manifesta-
tions (especially, but not limited to, fatigue, pruritus, symp-
toms due to splenomegaly, constitutional symptoms),
reduced quality of life, the emotional impact, the financial
impact of increased healthcare utilization and impaired
incomes. Pruritus, typically acquagenic, is the most frequent
and disabling complaint of patients with PV, and is reported
in up to 70% of cases.62 In extreme situations (approx.
15%)63 it causes severe disruption of the individual's life-
style, inducing sleep disturbances, depression, and impaired
working capabilities and social relationships. In a recent
landmark study into MPN in the United States that inter-
viewed 380 PV patients undergoing treatment, fatigue and
itching were identified by 33% and 9% of the respondents
as the symptom they most urgently wanted to resolve.64
The pathogenetic link between symptoms and clonal
myeloproliferation is likely sustained by an abnormal
release and signaling of inflammatory cytokines through
the deranged JAK/STAT pathway,65 a concept that is rein-
forced by the unique and rapid symptomatic efficacy of the
JAK1 and JAK2 inhibitor ruxolitinib.66
To add  to the burden associated with PV, one must con-
sider the side effects of treatment, including worsening of
fatigue and other signs of iron deficiency in heavily phle-
botomized patients, varying manifestations of intolerance
to hydroxyurea, the known toxicities of interferon, the
increased Herpes Zoster reactivation with ruxolitinib, to
name but a few. Presence of splenomegaly, use of hydrox-
yurea, and phlebotomy requirement are all independently
associated with a substantial symptom burden.67
Interestingly, a high symptomatic burden may occur inde-
pendently of conventional risk categories; therefore, some
low-risk patients might remain under-managed according
to current recommendations.67 Another component of the
PV-associated burden is the high incidence of co-existing
hematologic or solid cancers. In a study including 353 PV
patients, a 3.44-fold increased risk of lymphoproliferative
neoplasms, especially chronic lymphocytic leukemia, com-
pared with the general population, was reported.68 Among
2000 MPN patients from cancer registries, the prevalence of
all types of cancer was higher than in the general popula-
tion; in PV patients there was a significantly higher risk of
malignant skin melanoma.69
It is remarkable that recognition of disease-associated
burden, and the development of standardized approaches
for its quantification,70-72 such as the Myeloproliferative
Neoplasm Symptomatic Assessment Form (MPN-SAF),70
have been fostered by the development of JAK2 inhibitors
that proved unforeseen efficacy to ameliorate symptomatic
manifestations of MPN.29,30,66 It is worthy of note that such
scores have been integrated into the pivotal study leading to
approval of the use of ruxolitinib in PV.73
Defining end points for treatment
According to the European Leukemia Net (ELN) consen-
sus criteria, the goals of therapy in patients with PV are to
reduce the risk of first and/or recurrent thrombosis, prevent
bleeding events, minimize the risk of evolution to PPV-MF
and AML, and ameliorate the symptom burden.74 Revised
response criteria were released recently by the ELN and
IWG-MRT75 (Table 5). Three levels of responses are enlist-
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Table 5. Response criteria for polycythemia vera according to the ELN and IWG-MRT consensus.75
Complete remission
A Durable* resolution of disease-related signs including palpable hepatosplenomegaly, large symptoms improvement† AND
B Durable* peripheral blood count remission, defined as Ht lower than 45% without phlebotomies; platelet count < 400x109/L, WBC count
< 10x109/L, AND
C Without progressive disease, and absence of any hemorrhagic or thrombotic event, AND
D Bone marrow histological remission defined as the presence of age-adjusted normocellularity and disappearance of trilinear hyperplasia, 
and absence of > grade 1 reticulin fibrosis
Partial remission
A Durable* resolution of disease-related signs including palpable hepatosplenomegaly, large symptoms improvement† AND
B Durable* peripheral blood count remission, defined as Ht lower than 45% without phlebotomies; platelet count < 400x109/L, 
WBC count < 10x109/L, AND
C Without progressive disease, and absence of any hemorrhagic or thrombotic event, AND
D Without bone marrow histological remission defined as persistence of trilinear hyperplasia.
No response
Any response that does not satisfy partial remission
Progressive disease
Transformation into post-PV myelofibrosis, myelodysplastic syndrome or acute leukemia
ELN: European LeukemiaNet; IWG-MRT: International Working Group-Myeloproliferative neoplasms Research and Treatment; Ht: hematocrit; WBC: white blood cell count; PV:
polycythemia vera.*Lasting at least 12 weeks. †Large improvement in symptom(s) (≥10-point decrease) in MPN-SAF TSS.10 Molecular response is not required for assignment
as complete response or partial response. Molecular response evaluation requires analysis in peripheral blood granulocytes. Complete response is defined as eradication of
a pre-existing abnormality. Partial response applies only to patients with at least 20% mutant allele burden at baseline. Partial response is defined as 50% or more decrease in
allele burden. 
ed: complete response, partial response and no response.
The variables included regard the categories of clinico-
hematologic response (CHR, including normalization of
blood counts and spleen volume, and resolution of disease-
related symptoms), molecular response, and BM histology
response. The rationale to maintain separate categories of
response was the fact that there was no  evidence that avail-
able therapies alter the natural course of disease. Therefore,
while in clinical studies of new therapeutics it might be
worthwhile to address the achievement of a molecular or
histological response, these are not relevant in patients
receiving standard treatments. In fact, the ELN criteria were
developed mainly to allow for a reproducible design and
interpretation of clinical trials rather than for routine prac-
tice. Most patients with PV receiving conventional treat-
ment at best fulfill the criteria of partial response,76 although
most of those treated with interferon-amay achieve a CHR
(but not necessarily resolution of splenomegaly and/or
symptoms) and some also achieve a molecular response. In
a retrospective study of PV patients managed with hydrox-
yurea and followed for four years, no association was seen
between achievement of an ELN response and survival or
vascular complications.76 These findings, although biased
by the retrospective characteristics and the small size of the
study population, raise concerns about the real-life impact
of the ELN response criteria, and identify the need  for their
prospective evaluation, as well as a search for more power-
ful surrogate markers of clinical benefit. 
Interestingly, in the above cited MPN landmark study, the
most important treatment goals reported by patients were
slowing/delaying disease progression (25%), prevention of
thrombosis (24%), normalization of normal blood counts
(18%), better quality of life (12%), symptomatic improve-
ment (9%) and maintaining a hematocrit level less than
45% (6%).64
Evolving concepts in the treatment of patients
with PV
The basic concept: risk-adopted cytoreductive therapy 
The current treatment recommendations for patients
with PV rely on a few randomized studies and several con-
sensus/clinical practice indications. The first objective of
treatment is to reduce the hematocrit and associated blood
viscosity to minimize the risk of thrombosis. In a seminal
observational study, Pearson reported that the incidence of
thrombosis directly increased with hematocrit above a
level of 45%.77 This study claimed this  level of hematocrit
to be the optimal target for management, but a survey of
the practice patterns of American Society of Hematology
members revealed that, in practice, such a hematocrit
threshold was used by only a minority of physicians while
16% preferred to  adopt a target of 50%.78 It took almost
40 years to make the transition  from an observation/rec-
ommendation to an evidence-based guideline. The Cyto-
PV study randomly assigned 365 PV patients, irrespective
of risk category (approx. one-third were low-risk) and
treatment (phlebotomy, hydroxyurea, or both), to a target
level of less than 45% or 45%-50%.79 Results indicated
that patients in the higher hematocrit level had a 4-times
increased rate of death from cardiovascular events in com-
parison to those maintained at less than 45%.79 A lower
hematocrit level (ideally <42%) may be indicated (but not
formally proven) in women80 and/or in cases of SVT,
where RBC volume expansion is masked by hemodilu-
tion.  
How to maintain the target hematocrit level depends on
the risk category. For low-risk patients, phlebotomy is still
the cornerstone of treatment. For patients at high risk,
cytoreduction with hydroxyurea or interferon-a is recom-
mended. Cytoreduction is also indicated in low-risk
patients to control progressive leukocytosis (no threshold
formally identified) and thrombocytosis (usually above 1-
1.5 million/mm3), symptomatic splenomegaly and/or dis-
abling symptoms. In the non-randomized PVSG-08
study81 that included 51 treatment-naïve patients, use of
hydroxyurea was associated with a significantly lower
rate of thrombosis compared with the phlebotomy arm of
the PVSG-01 study (6.6% vs. 14% at 2 years).40
There is growing interest in the use of interferon-a as
first-line agent. The mechanisms by which interferon-a
induces responses in PV have not yet been clarified.
Interferon has pleiotropic activities, including effects on
immune modulatory cells, inhibition of apoptosis,
induced expression of pro-apoptotic genes, a direct anti-
proliferative effect on hematopoietic progenitor and possi-
bly stem cells (reviewed by Kiladjian et al.82). The efficacy
of interferon-a in inducing hematologic remission in PV
was first reported in 199883 (up-dated by Silver84) and con-
firmed in several small studies.82 Two larger independent
studies85,86 and one sponsored87 phase II study with differ-
ent preparations of pegylated interferon-a were reported.
These studies confirmed drug efficacy in inducing prompt
and sustained hematologic responses, eventually associat-
ed with improvement of symptoms and splenomegaly.
Furthermore, in most patients, a substantial decrease of
JAK2 mutant burden, usually after the first year of treat-
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Table 6. Definition of resistance/intolerance to hydroxyurea in polycythemia vera according to the ELN consensus.92
1. Need of phlebotomy to keep ht <45% after 3 months of at least 2 g/day of hydroxyurea, OR
2. Uncontrolled myeloproliferation, i.e. platelet count >400x109/L AND WBC >10x109/L after 3 months of at least 2 g/day 
of hydroxyurea, OR
3. Failure to reduce massive* splenomegaly by more than 50% as measured by palpation, OR failure to completely relieve symptoms related 
to splenomegaly after 3 months of at least 2 g/day of hydroxyurea, OR
4. Absolute neutrophil <1x109/L OR platelet count <100x109/L OR hemoglobin <100 g/L at the lowest dose of hydroxyurea required to achieve 
a complete or partial clinico-hematologic response#, OR
5. Presence of leg ulcers or other unacceptable hydroxyurea-related non-hematologic toxicities, such as mucocutaneous manifestations, 
gastrointestinal symptoms, pneumonitis or fever at any dose of hydroxyurea
ELN: European LeukemiaNet; Ht: hematocrit; WBC: white blood cell count.*Organ extending by more than  10 cm from the costal margin. #Complete response was defined as:
hematocrit less than 45% without phlebotomy, platelet count ≤400x109/L, WBC≤10x109/L or under, and no disease-related symptoms. Partial response was defined as: hematocrit
less than 45% without phlebotomy, or response in three or more of the other criteria.
ment and including also complete responses, was docu-
mented, although this was not found in other studies.88,89
Toxicity is lower with pegylated over conventional prepa-
rations of interferon, and a mono-pegylated interferon
that requires less frequent administrations might improve
tolerability.87 However, approximately 20% of the patients
stop interferon in the first year due to toxicity.
Interestingly, interferon-a is not approved for the treat-
ment of PV. Two randomized studies are ongoing, one
with interferon-a 2a (sponsored by the Myeloproliferative
Disorders-Research Consortium; registered at  clinicaltri-
als.gov identifier: 01259856), the other with pegylated inter-
feron-a 2b (the company sponsored PROUD-PV study;
registered at clinicaltrials.gov identifier: 1949805), both com-
pared with hydroxyurea. Results of these studies might
eventually provide the missing evidence to support an evi-
dence-based use of interferon as first-line agent; hopefully
this will lead to its approval for clinical use.
Second-line therapy: JAK2 inhibition
Most patients do pretty well with hydroxyurea for the
entire duration of their disease; however, 15%-20%
develop some intolerance or become resistant to the drug
over time.90,91 A set of consensus criteria are commonly
used to identify resistant or intolerant patients.92 The
development of cytopenias at the lowest dose of hydrox-
yurea needed to achieve a response was retrospectively
associated with an increased risk of death  and transfor-
mation to PPV-MF and AL.90
Patients who are not adequately controlled with therapy
or who develop an intolerance do not have many options. In
the case of intolerance, one common practice approach is to
reduce the daily dose to the best tolerated one and make
more generous use of phlebotomies to maintain the target
hematocrit. However, too many phlebotomies are not well
tolerated and may cause symptomatic iron deficiency. One
may switch from hydroxyurea to interferon, although this is
not supported by formal studies; vice versa hydroxyurea can
be used if interferon is not tolerated or effective. The use of
an alternative cytotoxic agent must be evaluated carefully,
particularly in younger subjects, due to the increased risk of
leukemia associated with alkylating agents after hydrox-
yurea.42,43 Recently, the JAK1 and JAK2 inhibitor ruxolitinib
has been approved for the treatment of patients with PV
who are refractory to, or intolerant of, hydroxyurea based
on the results of the phase III RESPONSE trial that enrolled
PV patients with baseline splenomegaly and phlebotomy
dependence.73 The study demonstrated superiority of ruxoli-
tinib versus best-available therapy (BAT) in controlling hema-
tocrit without phlebotomy and reduction of enlarged spleen
volume (the composite primary end point of the study,
reached by 22.7% vs. 0.9% of the patients); hematocrit and
spleen volume responses were maintained in 89% and 98%
of patients, respectively, at a median of 111 weeks of  expo-
sure.93 Less phlebotomies were required in the ruxolitinib
arm to maintain hematocrit less than 45%, and the number
of cardiovascular events was lower (1.8 vs. 8.2 in BAT per
100 patient-years); however, this end point was not statisti-
cally controlled, and interpretation of the findings remains
problematic. These results were largely in line with those of
the phase II study66 and have been further confirmed in the
phase III RESPONSE II study that enrolled patients with
similar characteristics but without palpable splenomegaly.94
Patients receiving ruxolitinib had significant improvement of
the MPN-SAF total symptom score that concerned all indi-
vidual symptoms related to splenomegaly, inflammatory
cytokines and microvascular abnormalities, unlike patients
receiving BAT who experienced no change or even a wors-
ening of symptoms. Treatment was usually well tolerated
with 82.7% of patients initially randomized to ruxolitinib
still on therapy at the 80-week update.93 However, patients
receiving ruxolitinib experienced more frequent reactivation
of Herpes Zoster infections (6.4% vs. 0 in BAT, mostly grade
1-2) and more non-melanoma skin cancers (4.4 vs. 2.0 in BAT
per 100-patient years; however, most cases developed in
patients with prior history of skin cancers), indicating that
active surveillance is required in daily practice and in long-
term follow-up analysis.
The unmet needs and perspectives for the future
Diagnostic criteria: too relaxed, too selective? 
Early diagnosis of PV is of the utmost importance to min-
imize the risk of thrombosis through the prompt adoption
of measures to control hematocrit, institution of anti-
platelet therapy, and correction of cardiovascular risk fac-
tors. Thanks to the availability of genetic tests for JAK2
mutation, and the revised WHO 2016 criteria, early diagno-
sis is possible. Although the use of the lower threshold lev-
els of hemoglobin set by the 2016 criteria might result in
some inappropriate investigations in subjects with modest,
yet sustained, increased hemoglobin without obvious rea-
son, “Paris is worth a mass”, and potentially preventing
thrombosis with prompt institution of therapy justifies the
additional costs. 
How to manage the risk of disease progression 
Due to a greater knowledge of disease pathophysiology,
earlier diagnosis and improved management, it might be
assumed that the median survival of patients with PV will
continue to improve mainly because of a reduction of life-
threatening thrombosis.36,56 Conversely, disappointingly, the
rate of progression to PPV-MF or AML/MDS has remained
unchanged over the years. Although some clinical and
molecular (p53,95,96 IDH1 and 2mutations97,98) variables have
been associated with increased risk of PPV-MF and
AML/MDS, none is specific enough to be clinically useful.
Furthermore, it has been argued that, because of the intrin-
sically low pace of progression, development of PPV-MF
may occur well before the worsening of fibrosis to the
grade 2 or more required by IWG-MRT criteria.99 There is,
therefore, the possibility that appropriate treatment, includ-
ing JAK inhibitors or stem cell transplantation, is delayed in
some patients. Given this, diagnosis of PPV-MF should not
be restrained by the degree of fibrosis, and novel diagnostic
criteria, ideally supported by hitherto unknown biomark-
ers, are needed. The genetic profile of AL after PV differs
from de novo leukemia for the notable absence of typical
abnormalities, including FLT3 and NPM-1. Survival from
post-PV AL is dismal, with a median of 3-5 months from
diagnosis,100,101 and no medical therapy, including induction
chemotherapy and ruxolitinib, provided evidence of effica-
cy,102,103 although stem cell transplantation is a curative
option in a few patients. Therefore, understanding the
molecular basis of transformation that will help identify
surrogate markers and develop effective therapeutic strate-
gies  represent urgent unmet needs. Notably, very few clin-
ical studies have been conducted, or indeed planned, in this
clinical setting. 
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The trouble with inheritance in a somatic disease
An extensive family history should be obtained during
the diagnostic workup in any PV patient. The knowledge
that PV, like other MPNs, may cluster in the family is a
cause of great concern for parents of PV patients. Increased
knowledge of the genetic basis of MPN and screening of
family members might in the future allow early disease
phases to be identified. However, at present, parents should
be discouraged from performing unnecessary tests in other-
wise healthy offspring, including driver mutations or
germline variants such as the 46/1 allele. 
Who is the “patient in need of treatment”?
The risk-adopted criteria in use for therapy do not formal-
ly account for additional variables that impact on thrombo-
sis rate, beyond history and age, as well as for the residual
approximate 2-fold risk over controls in conventionally
low-risk patients. Quantitative assessment of the sympto-
matic burden might allow patients to be better categorized
and has been widely used in clinical trials. However, how
to implement these tools in practice and how to use such
information for therapeutic decision making remain chal-
lenging  issues. Therefore, it is urgent to develop a defini-
tion of patients with “inadequately controlled disease” who
need to be shifted to second-line treatment, including rux-
olitinib, a highly effective, but costly, therapy.104 Patients
who continue to have  symptoms that are difficult to man-
age, or who manifest progressive symptomatic
splenomegaly or progressive leukocytosis/thrombocytosis,
or develop unacceptable toxicities with their current thera-
py, may obviously belong to that category of patients for
whom alternative treatment is required. However, the most
important indicator of an inadequately controlled PV in
terms of thrombosis and survival is the hematocrit level.79
Unfortunately, there is as yet no consensus  on what is the
“acceptable” rate of phlebotomies required, either alone (in
low-risk patients) or combined with cytoreduction (in high-
risk patients) to maintain the target level of hematocrit.
Furthermore, it was shown that patients with phlebotomy
requirements present a substantial symptomatic burden.67
Just based on the ELN criteria, need of (any) phlebotomy
after three months on an optimal dose of hydroxyurea
would per se be evidence of resistance to treatment, and
therefore of an inadequately controlled disease.92 However,
there is no hard evidence that this concept might be trans-
lated into the clinical practice. Timely action from the scien-
tific community to develop consensus criteria of what con-
stitutes an “inadequately controlled PV” is needed.
Antithrombotic prophylaxis: low-dose aspirin, 
anticoagulation, or both? 
Evidence from the ECLAP trial55 led to the recommenda-
tion of low-dose aspirin in all PV patients (unless contraindi-
cated) and this has certainly contributed to the  improve-
ment in outcome that has been observed since. However,
the rate of recurrent thrombosis, and the residual risk in
low-risk patients, remain unsatisfactorily high, and should
prompt studies of novel approaches for both primary and
secondary prophylaxis. From studies in non-PV patients,  it
might be assumed that twice daily aspirin is more effica-
cious against arterial, and possibly venous, thrombosis,
than once daily, but this still has to be proved, as does the
added value of combination therapy with oral anticoagu-
lants in patients with a history of venous events. The dura-
tion of anticoagulant prophylaxis in certain conditions, such
as SVT or pulmonary embolism, the added value of statins,
and the role of new direct oral anticoagulant are all ques-
tions that need to be  addressed in prospective studies.105
Do we want or need molecular remission? 
The BCR-ABL negativization produced by imatinib and
other TKIs in chronic myelogenous leukemia represents the
holy grail  for PV, too. However, it must be emphasized that
reduction/elimination of the JAK2V617F allele might not
necessarily be indicative of cure, since other mutated clones
preceding JAK2V617F acquisition, and also hematologic
abnormalities, may persist even in patients with complete
molecular remissions induced by interferon106 and ruxoli-
tinib.107 Therefore, while elimination of JAK2V617F mutat-
ed cells certainly constitutes a goal for novel therapies, the
impact of molecular responses on the natural history of dis-
ease remains uncertain and further studies are required. 
What’s available? 
Ruxolitinib is the first and only JAK2 inhibitor approved
for second-line treatment in PV; a phase II study with
another JAK2 inhibitor, momelotinib, is ongoing (clinicaltri-
als.gov identifier: 019898828). An alternative class of poten-
tially active drugs is made up by the histone deacethylase
inhibitors. Vorinostat was poorly tolerated, with 44% of
patients discontinuing treatment early.108 Givinostat proved
promising in a phase II study for control of hematocrit and
symptoms,109 and was also tested in combination with
hydroxyurea in patients who were refractory to this drug,
producing responses in approximately half.110 A phase Ib/II
study to assess the safety and tolerability, and preliminary
efficacy, in PV patients (clinicaltrials.gov identifier: 01901432)
is ongoing. Overall, not much is available and the shelf is
quite empty. Novel molecular insights are urgently needed
to boost pharmacological research.
Personalized medicine for PV: “what’s in a word?” 
After the discovery of aberrantly activated JAK/STAT
signaling as the basic pathogenetic defect, PV has potential-
ly entered the arena of personalized medicine. However, it
remains uncertain how to transfer this new  information
into the daily management of the individual patient.
Current therapeutic decisions are dictated by the needs of
the individual patient  and/or are based on predictive clini-
cal variables, such as age and history of thrombosis that are
not ‘druggable’, rather than by the disease itself. There is
some evidence of a ‘cure’, but we still do not know how
big an impact it might have on  long term-outcome, as
compared to optimized disease management, or how
expensive it would be (in terms of side effects and money)
to get it. Since new drugs may be more effective than con-
ventional ones, but are not without  toxicity and are costly,
predictive biomarkers need to be identified. In the mean-
while, fostering basic research, producing evidence-based
data and developing evidence-based recommendations
seem to be the most productive approach to move towards
personalized management of patients with PV.
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